Cian Healthcare

Why is Cian Healthcare Ltd falling/rising?

As of 30-Jun, Cian Healthcare Ltd's stock price is currently stable at Rs. 8.26, showing no change (0.00%). The stock has risen significantly over time, with a year-to-date increase of 50.73% and a 93.44% rise over the past year, but concerns about declining trading activity and investor participation may affect future price movements.

As of 30-Jun, Cian Healthcare Ltd's stock price is currently stable at Rs. 8.26, showing no change (0.00%). Despite this stability in the current price, the stock has demonstrated significant positive performance over various time frames. Year-to-date, the stock has risen by 50.73%, while over the past year, it has increased by 93.44%. <BR><BR>Today, the stock reached a new 52-week high of Rs. 8.26 and has outperformed its sector by 4.67%. Additionally, it has been gaining for the last two days, with a remarkable return of 64.87% during this short period. The stock is also trading above its moving averages across multiple time frames, indicating a strong upward trend.<BR><BR>However, there are some concerns regarding trading activity. The stock has experienced erratic trading, not trading on four out of the last twenty days, and there has been a significant decline in delivery volume, which has fallen by 96.08% compared to the five-day average. This suggests a decrease in investor participation, which could impact future price movements.<BR><BR>Overall, while the stock is currently stable, its recent performance and reaching a new high indicate a rising trend, despite some signs of declining investor engagement.

Which are the latest news on Cian Healthcare?

What does Cian Healthcare do?

Cian Healthcare Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, originally incorporated in 2003 and converted to a Public Limited Company in 2018. It currently has no available sales or profit data, with a market cap of INR 20 Cr and a negative return on equity of -17.58%.

Overview:<BR>Cian Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Cian Healthcare Limited was originally incorporated as a Private Limited Company on January 07, 2003, and later converted into a Public Limited Company with a name change on November 30, 2018. There is no recent sales or profit data available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 20 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A (Loss Making)<BR>Industry P/E: 20<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.53<BR>Return on Equity: -17.58%<BR>Price-to-Book: 0.47<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are in the management team of Cian Healthcare?

The management team of Cian Healthcare includes Suraj Zanwar (Managing Director), Munjaji Purbhaji Dhumal (Company Secretary & Compliance Officer), Swati Maheshwari (Independent Director), Paresh Arun Shah (Director), and Sunil Kumar (Independent Director).

The management team of Cian Healthcare includes the following individuals:<BR><BR>1. Suraj Zanwar - Managing Director<BR>2. Munjaji Purbhaji Dhumal - Company Secretary & Compliance Officer<BR>3. Swati Maheshwari - Independent Director<BR>4. Paresh Arun Shah - Director<BR>5. Sunil Kumar - Independent Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Cian Healthcare?

Cian Healthcare's peers include Ishita Drugs, Shree Ganesh Bio, Venmax Drugs, Centuple Global, Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Starsource Multi, Zenith Health, and Mono Pharmacare. Centuple Global shows good management risk and the highest 1-year return at 105.84%, while Shree Ganesh Bio has the lowest return at -33.71%.

Peers: The peers of Cian Healthcare are Ishita Drugs, Shree Ganesh Bio, Venmax Drugs, Centuple Global, Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Starsource Multi, Zenith Health, and Mono Pharmacare.<BR><BR>Quality Snapshot: Below Average management risk is observed at Ishita Drugs, Shree Ganesh Bio, Venmax Drugs, Parmax Pharma, Desh Rakshak, Dipna Pharmachem, and Zenith Health, while Good management risk is found at Centuple Global. Growth ratings show Excellent growth at Dipna Pharmachem, Average growth at Venmax Drugs, and the rest have Below Average growth. Capital Structure is rated as Good for Centuple Global, while the rest, including Ishita Drugs, Shree Ganesh Bio, Venmax Drugs, Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Cian Healthcare, Zenith Health, and Mono Pharmacare, have Below Average ratings.<BR><BR>Return Snapshot: Centuple Global has the highest 1-year return at 105.84%, while Shree Ganesh Bio has the lowest at -33.71%. Cian Healthcare's 1-year return of 100.00% is significantly higher than Shree Ganesh Bio's. Additionally, peers such as Venmax Drugs, Dipna Pharmachem, and Zenith Health have negative six-month returns.

When is the next results date for Cian Healthcare Ltd?

The next results date for Cian Healthcare Ltd is 30 May 2026.

The next results date for Cian Healthcare Ltd is scheduled for 30 May 2026.

How big is Cian Healthcare?

As of 24th July, Cian Healthcare Ltd has a market capitalization of 9.00 Cr, classifying it as a Micro Cap company. The latest balance sheet from March 2024 shows Shareholder's Funds of 57.74 Cr and Total Assets of 161.18 Cr, but recent quarterly performance data is unavailable.

As of 24th July, Cian Healthcare Ltd has a market capitalization of 9.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent quarterly performance data is unavailable, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>The latest reporting period for the balance sheet is March 2024, with Shareholder's Funds amounting to 57.74 Cr and Total Assets valued at 161.18 Cr.

Is Cian Healthcare overvalued or undervalued?

As of June 20, 2025, Cian Healthcare is considered risky and overvalued, with a PE ratio of -1.40 and an EV to EBITDA of -16.71, significantly underperforming compared to peers like Sun Pharma and Cipla, and has experienced a 1-year return of -83.14% against the Sensex's 6.36% return.

As of 20 June 2025, Cian Healthcare's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company is currently overvalued, with a PE ratio of -1.40, an EV to EBITDA ratio of -16.71, and a ROE of -11.99%. These figures suggest that the company's earnings and overall financial performance are under severe strain.<BR><BR>In comparison to its peers, Cian Healthcare's valuation metrics are starkly unfavorable. For instance, Sun Pharma has a PE ratio of 34.92 and an EV to EBITDA of 24.66, while Cipla boasts a PE ratio of 22.99 and an EV to EBITDA of 15.93, both indicating much stronger financial positions. Additionally, the company's recent stock performance has been poor, with a 1-year return of -83.14%, contrasting sharply with the Sensex's 6.36% return over the same period, further reinforcing the notion that Cian Healthcare is currently overvalued.

What is the technical trend for Cian Healthcare?

As of April 28, 2025, Cian Healthcare's technical trend is mildly bearish, with mixed signals from the MACD and moving averages, suggesting cautious optimism amid volatility concerns.

As of 28 April 2025, the technical trend for Cian Healthcare has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish, indicating mixed signals. The RSI shows no signal on the weekly chart but is bullish on the monthly, suggesting potential upward momentum over a longer time frame. Bollinger Bands indicate a bullish stance weekly but mildly bearish monthly, reflecting volatility concerns. Daily moving averages are mildly bearish, which aligns with the overall trend shift. Dow Theory is mildly bullish on both weekly and monthly charts, supporting a cautious outlook. Overall, the current technical stance is mildly bearish, driven primarily by the mixed MACD and moving averages.

How has been the historical performance of the Cian Healthcare?

Cian Healthcare's historical performance shows a decline in net sales and profits from March 2022 to March 2024, with net sales dropping from Rs 77.87 crore to Rs 61.70 crore and net profit decreasing from Rs 2.03 crore to Rs 0.25 crore. However, cash flow from operating activities improved significantly, rising to Rs 11.00 crore in March 2024.

Answer:<BR>The historical performance of Cian Healthcare shows fluctuations in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Cian Healthcare's net sales have decreased from Rs 77.87 crore in March 2022 to Rs 61.70 crore in March 2024, reflecting a downward trend. Total operating income followed a similar pattern, declining from Rs 77.87 crore in March 2022 to Rs 61.70 crore in March 2024. The total expenditure, excluding depreciation, also decreased from Rs 73.62 crore in March 2022 to Rs 50.83 crore in March 2024. Operating profit (PBDIT) showed some volatility, peaking at Rs 13.00 crore in March 2023 before dropping to Rs 11.31 crore in March 2024. Profit before tax was minimal at Rs 0.05 crore in March 2024, down from Rs 1.99 crore in March 2023. The net profit followed suit, decreasing from Rs 2.03 crore in March 2023 to Rs 0.25 crore in March 2024. The company's total assets increased slightly from Rs 156.54 crore in March 2020 to Rs 161.18 crore in March 2024, while total liabilities also rose from Rs 156.54 crore to Rs 161.18 crore during the same period. Cash flow from operating activities improved to Rs 11.00 crore in March 2024, up from Rs 4.00 crore in March 2023, indicating better cash generation despite the decline in net profit.

Who are the top shareholders of the Cian Healthcare?

The top shareholders of Cian Healthcare are Pankaj Shriniwas Zanwar with 13.76%, and Prakashchandra Rathi with 9.75%. Individual investors hold 63.56% of the shares, with no mutual fund or foreign institutional investor holdings, and pledged promoter holdings at 34.48%.

The top shareholders of Cian Healthcare include Pankaj Shriniwas Zanwar, who is the promoter with the highest holding at 13.76%. The highest public shareholder is Prakashchandra Rathi, holding 9.75%. Additionally, individual investors collectively hold a significant 63.56% of the company's shares. It's also noteworthy that there are no holdings by mutual funds or foreign institutional investors (FIIs), and the pledged promoter holdings stand at 34.4814%.

Has Cian Healthcare declared dividend?

No Dividend History Available